Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Adenocarcinoma

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

All Drugs and Chemicals

Anti-Infective Agents

Anticoagulants

Bone Density Conservation Agents

Amino Acids

Gallium 68 PSMA-11

Carbamide Peroxide

Edetic Acid

Pentetic Acid

Chelating Agents

Calcium

Calcium, Dietary

Radiopharmaceuticals

Lysine

Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on day 1.

Computed Tomography

Gallium Ga 68 Gozetotide

Positron Emission Tomography

Johannes Czernin

This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with intermediate or high risk prostate cancer before surgery. Diagnostic procedures, such as PET/CT scans, may help find and diagnose prostate cancer and find out how far the disease has spread.

PRIMARY OBJECTIVE:

I. To assess the sensitivity and specificity of gallium Ga 68 gozetotide (68Ga-PSMA-11) PET for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis, and on a per patient basis using nodal regional correlation.

SECONDARY OBJECTIVES:

I. To assess the positive and negative predictive value of 68Ga-PSMA-11 PET for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis, and on a per patient basis using nodal regional correlation.

II. To assess sensitivity, specificity, positive and negative predictive value of 68Ga- PSMA-11 PET for the detection of extra-pelvic nodal metastases, visceral metastases and osseous metastases compared to biopsy and imaging follow-up.

OUTLINE:

Patients receive 68Ga-PSMA-11 intravenously (IV) and undergo PET/CT scan over 20-50 minutes on day 1.

After completion of study, patients are followed up at 2-4 days, then at 12 months.

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

68Ga-PSMA-11 PET/CT for Staging of Intermediate and High Risk Prostate Cancer Prior to Radical Prostatectomy

Will be summarized by descriptive statistics.

Will compare patients with and without pelvic nodal metastases.

Assessed per Common Terminology Criteria for Adverse Events version 4.03.

Will be compared to tumor extent in histopathology.

Will be correlated with immunohistochemical stainings (e.g. PSMA, PI3K, Akt) and Gleason score.

Jonsson Comprehensive Cancer Center

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Antineoplastic Agents

Reproductive Control Agents

Androgens

Leuprolide

Goserelin

Antineoplastic Agents, Hormonal

Patients receive LHRH analogue comprising leuprolide acetate IM or goserelin acetate SC on day 1 and vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.

Patients receive LHRH analogue comprising leuprolide acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.

Goserelin Acetate

Laboratory Biomarker Analysis

Leuprolide Acetate

Vismodegib

Christopher Logothetis

This randomized phase I/II trial studies giving leuprolide acetate or goserelin acetate together with or without vismodegib followed by surgery to see how well they work in treating patients with prostate cancer that has spread from where it started to nearby tissue or lymph nodes. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate or goserelin acetate, may lessen the amount of androgens made by the body. Vismodegib may slow the growth of tumor cells. Giving antihormone therapy together with vismodegib may be an effective treatment for prostate cancer.

PRIMARY OBJECTIVES:

I. To assess the difference in less than or equal to 5% tumor involvement between patients between the two arms.

SECONDARY OBJECTIVES:

I. To assess differences in hedgehog signaling, androgen signaling, markers linked to high grade prostate cancer (PCa) progression, proliferation, apoptosis, and the expression of androgen producing enzymes in the tumor microenvironment between the two arms.

II. To assess safety of preoperative GDC-0449 (vismodegib) in combination with luteinizing hormone-releasing hormone (LHRH).

III. To assess the difference in proportion of patients with negative disease surgical margins between the two arms.

IV. To collect and archive tissue from the primary tumor, bone marrow and blood (serum, plasma), bone marrow aspirate for future study.

V. To assess difference in relapse rate (biochemical, objective) and time to progression.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I (androgen-ablation therapy and vismodegib): Patients receive LHRH analogue comprising leuprolide acetate intramuscularly (IM) or goserelin acetate subcutaneously (SC) on day 1 and vismodegib orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.

ARM II (androgen-ablation therapy): Patients receive LHRH analogue comprising leuprolide acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients undergo radical prostatectomy.

After completion of study therapy, patients are followed up every 6 months for up to 8 years.

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients With Locally Advanced Adenocarcinoma of the Prostate

Will be descriptively summarized. PSA recurrence is defined as two (2) serial measureable rises in PSA concentration above the undetectable level with the standard assay (\> 0.1 ng/mL).

Each patient's pathologic staging will be assessed from the samples collected from prostatectomy. Will be descriptively summarized. Two-sided Chi-Square test will be used to provide the test of significance between the 2 groups of LHRHa versus LHRHa plus vismodegib.

National Cancer Institute (NCI)

All adverse events reported as routine part of a clinical trial.

Group A will receive 150mg GDC-0449 daily for 3 months prior to radical prostatectomy.

Group A- GDC-0449 and Androgen Ablation (LHRHa)

Patients will receive an LHRHa (monthly injection or three-month injection) for a maximum of 4 months before a prostatectomy is performed.

Group B- Androgren Ablation (LHRHa) Alone

Group- B Androgren Ablation (LHRHa) Alone

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Logothetis, Christopher, M.D. / Genitourinary Medical Oncology

Group A will receive 150mg GDC-0449 daily for 3 months prior to radical prostatectomy

Group A-GDC-0449 and Androgen Ablation (LHRHa

Group B Androgen Ablation (LHRHa) Alone

Proportion of Patients With =< 5% Tumor Involvement

Differences in Relapse Rates by PSA Levels (Biochemical)

Time to PSA (Biochemical) Progression, Defined as PSA Recurrence

Time to PSA (Clinical) Progression, Defined as a Serial Rise in PSA Concentration in the Presence of Castrate Serum Testosterone Concentration or Radiographic Evidence of Progression

Proportion of Patients With PSA =< 0.2 ng/mL

Differences in the Rate of Positive Surgical Margins Between the Two Groups

Differences in Relapse Rates by Bone Scan/Computed Tomography Scan (Objective)

Proportion of Patients Expressing Differences in Hedgehog, Androgen Signaling and Related Genes Markers

Overall Study

Herbal and Botanical

Pomegranate

Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).

Patients receive placebo PO QD for 52 weeks (+/- 1 week).

Pharmacological Study

Placebo

Pomegranate-Extract Pill

David F Jarrard

This randomized phase II trial studies pomegranate-extract pill in preventing tumor growth in patients with prostate cancer that is limited to a certain part of the body (localized), who have chosen observation as their treatment plan. The use of pomegranate-extract pill may slow disease progression in patients with localized prostate cancer.

PRIMARY OBJECTIVES:

I. To determine the effect of pomegranate fruit extract (PFE) 1000 mg, taken daily for 1 year, on the plasma levels of insulin-like growth factor (IGF-1) from baseline to end of study (52 weeks) in participants undergoing active surveillance (AS) for early stage prostate cancer.

SECONDARY OBJECTIVES:

I. To assess compliance with a once daily oral administration of PFE versus placebo over a 52-week period of time.

II. To assess the toxicity of PFE vs. placebo when taken daily for 52 weeks (+/- 1 week).

III. To compare and correlate the effect of 52 weeks of daily dosing with PFE vs placebo on the end of study biopsy results including the presence or absence of tumor, the extent of tumor and Gleason scores.

IV. To compare and correlate the modulation of the following biomarkers with response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core, tumor tissue from a positive core, and normal tissue adjacent to tumor from a positive core; plasma: insulin-like growth factor 1/IGF binding protein 3 ratio (IGF-1/IGFBP-3 ratio); prostate tissue (normal and abnormal): apoptosis (CASPASE 3), Ki-67, 8OHdG, IGF-1R, androgen receptor, IGF-1, IGFBP-3, prostate specific antigen (PSA).

V. Measure PFE constituents/metabolites in plasma and urine for evidence of accumulation (trough levels): ellagic acid, dimethyl ellagic acid, dimethyl ellagic acid glucuronide (DMEAG), urolithin A, urolithin A-glucuronide, urolithin B and urolithin B-glucuronide.

VI. Measure PSA doubling time (PSA DT) in serum, using the calculation provided on the Memorial Sloan Kettering Cancer Center website.

VII. To assess the feasibility of cancer chemoprevention trials in a population of men undergoing active surveillance for prostate cancer.

VIII. Measurement of serum testosterone.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive pomegranate-extract pill orally (PO) once daily (QD) for 52 weeks (+/- 1 week).

GROUP II: Patients receive placebo PO QD for 52 weeks (+/- 1 week).

Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance

A Phase IIA Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract/Pomx™ in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance

The primary endpoint for modulation of intermediate endpoint biomarkers will be the change in the plasma levels of IGF-1 by a quantitative assay (ELISA) from pre-study to post-treatment. The difference between these time points for the placebo group and the pomegranate fruit extract (PFE) group will be tested using a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test.

Summarized by treatment arm with descriptive statistics, and tested for imbalance using Wilcoxon rank-sum test. Reported for each visit per protocol at Week 13, Week 26, Week 39, and Week 52 (end of study).

Patient toxicity throughout the study will be summarized in several ways; the presence or absence of any toxicity, worst CTCAE grade, and strongest investigator-defined relationship will all be examined and characterized by treatment arm, and analyzed appropriately (Wilcoxon rank-sum for ordinal data, Fisher's exact test for dichotomous data, and log rank test for time to event data).

Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.

PSA DT will be determined from PSA values obtained during study participation (baseline and weeks 13, 26, 39 and 52). The secondary endpoint of PSA DT is based on the value at study completion (week 52 or at point of early termination). However, PSA DT will be determined starting at week 26 (the earliest time point with 3 values) and week 39 and recorded. PSA doubling time is a measure based on the slope of the PSA at multiple time points. If the slope is relatively flat, the predicted doubling time could be far beyond the length of the actual study. As such, the value is not limited to the time frame over which data is collected from the participant.

Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core ("benign" in results), tumor tissue from a positive core ("tumor" in results), and normal tissue adjacent to tumor from a positive core ("adjacent" in results). Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.

Compare and correlate biomarker modulation in response to PFE versus placebo in three areas of interest: tissue from a completely benign biopsy core ("benign" in results), tumor tissue from a positive core ("tumor" in results), and normal tissue adjacent to tumor from a positive core ("adjacent" in results). Measurements for each are per nuclear ("Nuc" in results), cytoplasmic ("Cyt" in results), and cellular ("Cell" in results) basis. Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.

The Gleason Score is a grading system used to determine the aggressiveness of prostate cancer, scored 1-5 with 1 being healthy tissue and 5 being abnormal. Prostate cancers are assigned 2 scores to define the 2 most prevalent tissue types. They are added together (total range of 2-10). Typical scores fall between 6-10, the higher the overall score, the more likely the cancer will spread.

Change in the length of biopsy cores that contained cancerous tissue from Baseline to end of study.

Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).

Laboratory Biomarker Analysis: Correlative studies

Pharmacological Study: Correlative studies

Pomegranate-Extract Pill: Given PO

Group I (Pomegranate-extract Pill)

Patients receive placebo PO QD for 52 weeks (+/- 1 week).

Laboratory Biomarker Analysis: Correlative studies

Pharmacological Study: Correlative studies

Placebo: Given PO

Group II (Placebo)

Participant Age

Age, Customized

The final report for this study contains data for participant 'gender', the study team would like to note this for consistency.

Eastern Cooperative Oncology Group (ECOG) 0 = Fully active, able to carry on all pre-disease performance without restriction

1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work

ECOG Performance Status

Systolic Blood Pressure

Diastolic Blood Pressure

Temperature

Pulse

Height

Weight

Body Mass Index

Skin

Prostate

Head/Eyes/Ears/Neck/Throat

Neurological

Abdomen

Genitalia

History or Baseline Presence of Disease / Abnormality

3+3=6

3+4=7

Gleason Score

David Jarrard

Change in Plasma IGF-1 From Baseline to Post-Treatment

Week 13

Week 26

Week 39

End of Study (Week 52)

One participant has no compliance values for weeks 26 and 39.

Compliance: Number of Participants Who Took Study Drug Per Protocol

Any Adverse Event

Multiple Adverse Events

Grade 3 (Severe) or Worse

Serious Adverse Events

Incidence of Adverse Events Graded Per Common Terminology Criteria for Adverse Events (CTCAE)

Change Baseline to Week 13

Change Baseline to Week 26

Change Baseline to Week 39

Change Baseline to Week 52

Change in Plasma Biomarker Levels From Baseline: IGFBP-3

Change in Plasma Biomarker Levels From Baseline: IGF-1/GFBP-3

Change from Baseline Week 26

Change from Baseline Week 39

Statistician notes that serum PSA data is missing for one participant in the pomegranate extract arm for all time points, missing for another in the pomegranate arm at week 39, and one from the placebo arm at week 39.

Change in Total Serum Prostate Specific Antigen (PSA) From Baseline

comparison of both arms at end of study, week 52

Baseline

Week 52

Patients receive pomegranate-extract pill orally once a day for 52 weeks (+/- 1 week).

Laboratory Biomarker Analysis: Correlative studies

Pharmacological Study: Correlative studies

Pomegranate-Extract Pill: Given PO

Patients receive placebo orally once a day for 52 weeks (+/- 1 week).

Laboratory Biomarker Analysis: Correlative studies

Pharmacological Study: Correlative studies

Placebo: Given PO

Change in Serum Testosterone

One of the participant's PSA values were 'non-detectable', therefore PSA observations could not be calculated for that participant.

Prostate Specific Antigen Doubling Time (PSA DT)

Change From Baseline: Benign

Change From Baseline: Adjacent

Change From Baseline: Tumor

The number analyzed depends on the identification and recovery of relevant tissue type (benign, adjacent, tumor).

Change in Tissue Biomarker Levels: PSA

Change from Baseline: IGF-1 Adjacent (Nuc)

Change from Baseline: IGF-1 Adjacent (Cyt)

Change from Baseline: IGF-1 Benign (Cell)

Change from Baseline: IGF-1 Adjacent (Cell)

Change From Baseline: Nuc Benign

Change From Baseline: Nuc Adjacent

Change From Baseline: Nuc Tumor

Change From Baseline: Cyt Benign

Change From Baseline: Cyt Adjacent

Change From Baseline: Cyt Tumor

Change From Baseline: Cell Benign

Change From Baseline: Cell Adjacent

Change From Baseline: Cell Tumor

Change in Tissue Biomarker Levels: IGF-1

Change From Baseline: Nuc Adjacent p-value

Change From Baseline: Cyt Adjacent p-value

Change From Baseline: Cell Benign p-value

Change From Baseline: Cell Adjacent p-value

Change in Tissue Biomarker Levels: IGFBP-3

Change in Tissue Biomarker Levels: CASP3

Change From Baseline:Tumor

Change in Tissue Biomarker Levels: Ki-67

Change from Baseline: Nuc Adjacent p-value

Change from Baseline: Cyt Adjacent p-value

Change from Baseline: Cell Benign p-value

Change from Baseline: Cell Adjacent p-value

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery	NCT03368547	Prostate Adenoc... Stage IIB Prost... Stage III Prost... Stage IV Prosta...	Computed Tomogr... Gallium Ga 68 G... Positron Emissi...	-	Jonsson Comprehensive Cancer Center
Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer	NCT01163084	Prostate Adenoc... Stage IIA Prost... Stage IIB Prost...	Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Vismodegib	18 Years -	National Cancer Institute (NCI)
Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance	NCT02095145	PSA Level Less ... PSA Level Less ... Stage I Prostat... Stage II Prosta... Stage IIA Prost... Stage IIB Prost...	Laboratory Biom... Pharmacological... Placebo Pomegranate-Ext...	21 Years -	National Cancer Institute (NCI)
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer	NCT01251861	Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost...	Akt Inhibitor M... Bicalutamide Clinical Observ... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)

Spots Global Cancer Trial Database for stage iib prostate cancer ajcc v7